GeneDx Holdings Corp. WGS
65.72 USD +3.35 (+5.37%)
At closeNov 10, 2026, 4:16 AM EST
59.12 -6.60 -10.04%
Pre-market · Nov 10, 4:16 AM ET
61.47 Day range 67.40
32.21 52-week range 170.87
- YTD
- -49.47%
- 1 year
- -52.97%
- Market cap
- 1.96B
- Revenue (ttm)
- 454.43M
- Profit margin
- -23.41%
- EPS (ttm)
- -3.63
- Shares out
- 29.82M
- Forward P/E
- 54.83
- YTD return
- -49.47%
- 1-year return
- -52.97%
- Volume
- 1.81M
- Avg volume
- 720.10K
- Open
- 63.19
- Previous close
- 62.37
- Day's range
- 61.47 – 67.40
- 52-week range
- 32.21 – 170.87
- Beta
- 1.99
- Analysts
- Strong Buy
- Price target
- 93.50 (+42.3%)
- Earnings date
- Feb 22, 2027
5D +0.19 (+0.29%)
Key statistics
- Enterprise value
- 1.89B
- PEG ratio
- 0.00
- Price / sales
- 4.31
- Price / book
- 8.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 11.40%
- Free cash flow
- -47.50M
- Total cash
- 132.55M
- Total debt
- 167.40M
- Return on equity
- -40.80%
- Short % of float
- 38.65%
- 50-day average
- 76.83
- 200-day average
- 70.98
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 93.50 +42.3% upside
Now 65.72
- Target (low)
- 83.00
- Target (mean)
- 93.50
- Target (high)
- 103.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate 0.07286.
Financials — quick view
WGS Revenue — quarterly 114.44M
WGS Net income — quarterly -17.74M
WGS EPS — quarterly -0.60
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | 0.31 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | 0.07286 | 0.28 | +0.21 | +284.30% |
| Aug 3, 2026 | Jun 30, 2026 | -0.18787 | 0.01 | +0.20 | +105.32% |
| May 4, 2026 | Mar 31, 2026 | -0.06 | -0.28 | -0.22 | -366.67% |
| Feb 23, 2026 | Dec 31, 2025 | 0.11 | 0.14 | +0.03 | +27.27% |
| Oct 28, 2025 | Sep 30, 2025 | 0.28 | 0.49 | +0.21 | +75.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Aug 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 4, 2026 | BTIG | reit | Buy | Buy |
| Jun 29, 2026 | Guggenheim | main | Buy | Buy |
| Jun 23, 2026 | Piper Sandler | main | Overweight | Overweight |
| May 5, 2026 | Canaccord Genuity | main | Buy | Buy |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- genedx.com
News
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript 
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability 
GeneDx Q3 Earnings Call Highlights 
GeneDx Holdings Q3 2026 Earnings Call Transcript 
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est 
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing 
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday 
12 Health Care Stocks Moving In Friday's After-Market Session 
GeneDx Plans To Enhance Its Genome Testing Portfolio With Long-Read Whole Genome Sequencing
Your note
Sign in to keep a note on WGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASDIN CAPITAL, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 4, 2026 | 0 |
| CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 17, 2026 | 4,083,650 |
| FEELEY KEVIN | Chief Financial Officer | Sale | Sep 8, 2026 | 41,476 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 17, 2024 | 2,719,690 |
| LEPROUST EMILY M | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 24,852 |
| MEISTER KEITH A | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 17, 2026 | 5,141,420 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Corvex Management LP | 16.04% | 4,784,570 | 314.44M | Jun 29, 2026 |
| Casdin Capital, LLC | 12.43% | 3,707,164 | 243.63M | Jun 29, 2026 |
| Blackrock Inc. | 5.72% | 1,706,239 | 112.13M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.60% | 1,669,441 | 109.72M | Jun 29, 2026 |
| ARK Investment Management, LLC | 5.40% | 1,610,189 | 105.82M | Jun 29, 2026 |
| William Blair Investment Management, LLC | 5.23% | 1,560,247 | 102.54M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 3.74% | 1,116,678 | 73.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.04% | 607,773 | 39.94M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.74% | 518,235 | 34.06M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.73% | 515,373 | 33.87M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 0.89% | 266,042 | 17.48M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.84% | 249,890 | 16.42M | Jun 29, 2026 |